Get the Stockscreener App
3.03
37.32%
-1.82
Artelo Biosciences Inc stock is traded at $3.03, with a volume of 763.77K.
It is down -37.32% in the last 24 hours and down -18.28% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$4.85
Open:
$2.955
24h Volume:
763.77K
Relative Volume:
0.65
Market Cap:
$2.22M
Revenue:
-
Net Income/Loss:
$-12.88M
P/E Ratio:
-0.085
EPS:
-35.6417
Net Cash Flow:
$-8.79M
1W Performance:
-57.54%
1M Performance:
-18.28%
6M Performance:
-81.61%
1Y Performance:
-82.61%
1-Day Range:
$2.955
$3.38
1-Week Range:
$2.955
$9.80
52-Week Range:
$2.955
$85.80
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
3.01 | 3.57M | 0 | -12.88M | -8.79M | -35.64 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Algorand Edges Lower: No Catalysts Amid Pharma Noise - Bitget
Artelo Biosciences (ARTL) Explores New Avenues for Muscle Preser - GuruFocus
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments - The Manila Times
GLP-1 weight loss can cut lean mass; Artelo starts protection study - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Artelo Biosciences Expands Clinical Pipeline into Glaucoma Market with Investigator-Sponsored Study - Quiver Quantitative
Artelo Biosciences Expansion into $16.3B Glaucoma Market, - GlobeNewswire
ARTLW (Artelo Biosciences) PB Ratio : (As of Mar. 25, 2026) - GuruFocus
[S-1] ARTELO BIOSCIENCES, INC. F... - Stock Titan
Artelo Biosciences (ARTL) seeks $10.9M in dilutive stock and warrant raise - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nano-cap Artelo Biosciences stock explodes — glaucoma study collaboration ignites rally - MSN
[S-1/A] ARTELO BIOSCIENCES, INC. Amends IPO Registration Statement - Stock Titan
Why is ARTL stock soaring pre-market today? - MSN
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Artelo Biosciences Surges with Groundbreaking Glaucoma Study Announcement - timothysykes.com
Artelo Biosciences (NASDAQ: ARTL) details $10.8M S-1 stock sale - Stock Titan
Artelo Biosciences, Inc.Common Stock (NQ: ARTL - The Chronicle-Journal
Artelo Biosciences Surges on Glaucoma Study Announcement - StocksToTrade
Artelo Biosciences Jumps 28% During the Day Amid Uncertainty Fueling Market Fluctuations and Rumors - Bitget
Artelo Biosciences Surges 28% Intraday as Mystery Drives Volatility and Speculation - Bitget
Artelo Biosciences Expands Market Footprint: Stock Soars Amid Glaucoma Study Initiatives - timothysykes.com
Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill
Small Cap Stocks To Watch Now – March 18th - Defense World
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
3 Penny Stocks to Watch Now, 3/19/26 - TipRanks
Artelo Biosciences Enters Securities Purchase Agreements for Bridge Notes with Vanquish Funding Group and Boot Capital LLC - Minichart
Artelo Biosciences Secures Bridge Financing Through Note Issuance - TipRanks
Artelo Biosciences Raises $310,000 in 12% Bridge Notes From Vanquish and Boot - TradingView
Artelo Biosciences (NASDAQ: ARTL) raises cash via 12% bridge notes - Stock Titan
Artelo Biosciences, Inc. 2025 Financial Results: Going Concern Risks, Capital Raises, and Significant Losses Detailed in Annual Report - Minichart
Small Cap Stocks To Watch NowMarch 18th - MarketBeat
Why Is Artelo Biosciences Stock Surging Today?Artelo Biosciences (NASDAQ:ARTL) - Benzinga
Artelo Biosciences completes 1-for-3 reverse stock split By Investing.com - Investing.com India
Artelo Biosciences (ARTL) Soars 40% After Securing Fully-Funded Glaucoma Trial Partnership - MEXC
Artelo Biosciences stock surges on glaucoma study agreement By Investing.com - Investing.com South Africa
Artelo Biosciences stock surges on glaucoma study agreement - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Artelo Biosciences moves into glaucoma research with fully funded clinical study - MSN
Artelo Biosciences (ARTL) Stock Jumps 40% on Surprise Glaucoma Study News - MEXC
Artelo announces third-party fully funded clinical study agreement for ART27.13 - TipRanks
Artelo Biosciences’ Stock Increases with Positive R&D Updates - StocksToTrade
Artelo Biosciences jumps as it expands ART27.13 into glaucoma via fully funded clinical study - Quiver Quantitative
Artelo Biosciences (ARTL) Stock Rockets 40% Following Glaucoma Trial Partnership - parameter.io
Artelo Biosciences Shares Surge Amid Promising Research Updates - timothysykes.com
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
Morning Market Movers: ARTL, SWMR, OVID, HIT See Big Swings - RTTNews
Artelo Biosciences (ARTL) Explores New Glaucoma Treatment in Upc - GuruFocus
Why Is ARTL Stock Soaring Pre-Market Today? - Asianet Newsable
Artelo Biosciences and Belfast Health and Social Care Trust Enter Definitive Investigator-Initiated Study Agreement - marketscreener.com
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study - marketscreener.com
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):